

PART III: BIBLIOGRAPHY

Original Articles:

1. **Hasan T**, Sims LB, Fry A. Heavy atom isotope effect studies of elimination reaction mechanisms: a kinetic and carbon-14 kinetic isotope effect study of the base-promoted dehydrochlorination of substituted 1-Phenylethyl-14C chlorides. *J Am Chem Soc* 1983;105:3967-75.
2. Goldman RA, **Hasan T**, Hall CC, Strycharz WA, Cooperman BS. Photoincorporation of tetracycline into *Escherichia coli* ribosomes: identification of the major proteins photolabeled by native tetracycline and tetracycline photoproducts and implications of the inhibitory action of tetracycline on protein synthesis. *Biochemistry* 1983; 22:359-68.
3. Kerlavage AR, **Hasan T**, Cooperman BS. Reverse-phase high performance liquid chromatography of *escherichia coli* ribosomal proteins: standardization of 70S, 50S, and 30S protein chromatograms: functional activity of purified proteins. *J Biol Chem* 1983; 258:6313-18.
4. Kerlavage AR, Weitzmann CJ, **Hasan T**, Cooperman BS. Reverse-phase high-performance liquid chromatography of *escherichia coli* ribosomal proteins: characteristics of the separation of a complex protein mixture. *J Chromatography* 1983; 226:225-37.
5. **Hasan T**, Kochevar IE, McAuliffe DJ, Cooperman BS, Abdulah D. Mechanism of tetracycline phototoxicity. *J Invest Dermatol* 1984; 83:179-83.
6. **Hasan T**, Kochevar IE, Abdulah D. Amiodarone phototoxicity to human erythrocytes and lymphocytes. *Photochem Photobiol* 1984; 40:715-19.
7. **Hasan T**, Cooperman BS. Reversed-phase high performance liquid chromatographic separations of tetracycline derivatives using volatile mobile phases. *J Chromatography* 1985; 321:462-66.
8. **Hasan T**, Allen M, Cooperman BS. Anhydrotetracycline is a major product of tetracycline photolysis. *J Org Chem* 1985; 50(10):1755-57.
9. **Hasan T**, Goldman R, Cooperman BS. Photoaffinity labeling of the tetracycline binding site of the *escherichia coli* ribosome: the use of a high intensity light source and of radioactive sancycline derivatives. *Biochem Pharmacol* 1985; 34(7):1065-71.
10. **Hasan T**, Khan AU. Phototoxicity of the tetracyclines: photosensitized emission of singlet delta dioxygen. *Proc Natl Acad Sci* 1986; 83:4604-06.
11. Shea C, Wimberly J, **Hasan T**. Mitochondrial phototoxicity sensitized by doxycycline in cultured human carcinoma cells *in vitro*. *J Invest Dermatol* 1986; 87(3):338-42.
12. Oseroff A, Ohuoha D, **Hasan T**, Bommer JC, Yarmush ML. Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. *Proc Natl Acad of Sci* 1986; 83:8744-48.
13. Shea CR, Whitaker D, Murphy GF, **Hasan T**. Ultrastructure and dynamics of selective mitochondrial injury in carcinoma cells after doxycycline photosensitization *in vitro*. *Am J Pathol* 1988; 133(2):391-98.
14. Shea CR, Long F, Deutsch T, **Hasan T**. Doxycycline-sensitized phototoxicity following excimer laser irradiation: effects of irradiance. *Lasers in the Life Sciences* 1988;2(1):29-38.
15. **Hasan T**, Lin CW, Lin A. Laser-induced selective cytotoxicity using monoclonal antibody-chromophore conjugates. *Prog Clin Biol Res* 1989; 288:471-77.
16. **Hasan T**, Lin A, Yarmush D, Oseroff A, Yarmush M. Monoclonal antibody-chromophore conjugates as selective phototoxins. *J Control Release* 1989; 10(1):107-17.
17. Shea CR, Chen N, **Hasan T**. Dynamic aspects of rhodamine dye photosensitization *in vitro* with an argon-ion laser. *Laser Surg Med* 1989; 9:83-89.

18. Shea CR, Chen N, Wimberly J, **Hasan T**. Rhodamine dyes as potential agents for photochemotherapy of cancer in human bladder carcinoma cells. *Cancer Res* 1989; 49:3961-65.
19. Shea CR, Sherwood ME, Flotte TJ, Chen N, Scholz M, **Hasan T**. Rhodamine 123 phototoxicity in laser-irradiated MGH-U1 human carcinoma cells studied in vitro by electron microscopy and confocal laser scanning microscopy. *Cancer Res* 1990; 50:4167-72.
20. Shea CR, Hefetz Y, Gillies R, Wimberly J, Dalickas G, **Hasan T**. Mechanistic investigation of doxycycline photosensitization by picosecond-pulsed and continuous-wave laser irradiation of cells in culture. *J Biol Chemistry* 1990; 265(11):5977-82.
21. Ortel B, Gange RW, **Hasan T**. Investigations of a manganese-containing mimic of superoxide dismutase in riboflavin phototoxicity in human cells in vitro. *Photochem Photobiol* 1990; 7:261-76.
22. Bachor R, Shea CR, Gillies R, **Hasan T**. Photosensitized destruction of human bladder carcinoma cells treated with chlorin-e6 conjugated microspheres. *Proc Natl Acad Sci* 1991; 88:1580-84.
23. Goff B, Bamberg M, **Hasan T**. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. *Cancer Res* 1991; 51:4762-67.
24. Bachor R, Scholz M, Shea C, **Hasan T**. Mechanism of photosensitization by microsphere-bound chlorin e6 in human bladder carcinoma cells. *Cancer Res* 1991; 51:4410-14.
25. Bachor R, Shea C, **Hasan T**. Free and conjugated chlorin e6 in the photodynamic therapy of human bladder carcinoma cells. *J Urology* 1991;146:1654-58.
26. Hanada K, Gange RW, Siebert E, **Hasan T**. Protective effects of cadmium chloride against UVB injury in mouse skin and in cultured human cells: a possible role of cadmium-induced metallothionein. *Photodermatol Photo* 1991; 8:111-15.
27. Roberts WG, **Hasan T**. Role of neovasculature and vascular permeability on the tumor retention of photodynamic agents. *Cancer Res* 1992; 52(4):924-30.
28. Ortu P, LaMuraglia G, Roberts G, Flotte T, **Hasan T**. Photodynamic therapy of arteries: a novel approach for the treatment of experimental intimal hyperplasia. *Circulation* 1992; 85(3):1189-96.
29. Bachor R, Flotte T, Scholz M, Dretler S, **Hasan T**. Comparison of interavenous and intravesical administration of chloro-aluminum sulfonated phthalocyanine for photodynamic treatment in a rat bladder cancer model. *J Urology* 1992; 147(5):1404-10.
30. Goff BA, Bachor R, Kollias N, **Hasan T**. Effects of photodynamic therapy with topical application of 5-aminolevulinic acid on normal skin of hairless guinea pigs. *J Photochem Photobiol B:Biological* 1992; 15:239-51.
31. Bhatta N, Anderson R, Flotte TJ, Schiff I, Nishioka N, **Hasan T**. Endometrial ablation by means of photodynamic therapy with Photofrin II. *Am J Obstet Gynecol* 1992; 167(6):1856-63.
32. Roberts WG, **Hasan T**. Tumor-secreted vascular endothelial growth factor influences photosensitizer uptake. *Cancer Res* 1993; 53:1-5.
33. LaMuraglia GM, Ortu P, Flotte TJ, Roberts WG, Schomacker KT, Chandrasekar NR, **Hasan T**. Chloroaluminum sulfonated phthalocyanine partitioning in normal and intimal hyperplastic artery in the rat: implications for photodynamic therapy. *Am J Pathol* 1993; 142(6):1-9.
34. Frisoli JK, Schomacker KT, Tudor EG, Flotte TJ, **Hasan T**, Deutsch TF. Pharmacokinetics of a fluorescent drug using laser-induced fluorescence. *Cancer Res* 1993; 53:5954-61.
35. Shea CR, Olack GA, Morrison H, Chen N, **Hasan T**. Phototoxicity of lumidoxycycline. *J Invest Dermatol* 1993; 101(4):1-5.
36. LaMuraglia GM, ChandraSekar NR, Flotte TJ, Abbott WM, Michaud N, **Hasan T**. Photodynamic therapy inhibition of experimental intimal hyperplasia: acute and chronic effects. *J Vasc Surg* 1994; 19:321-31.

37. Schmidt U, Bauman W, Gragoudas E, Flotte TJ, Michaud NA, Birngruber R, **Hasan T**. Photodynamic therapy of experimental choroidal melanoma using a lipoprotein-delivered benzoporphyrin. *Ophthalmology* 1994; 101(1):89-99.
38. Iinuma S, Farshi SS, Ortel B, **Hasan T**. A mechanistic study of cellular photodestruction with 5-aminolevulinic acid-induced porphyrin. *Brit J Cancer* 1994; 70:001-8.
39. Aveline B, **Hasan T**, Redmond RW. Photophysical and Photosensitizing Properties of Benzoporphyrin Derivative Monoacid Ring A (BPD-MA). *Photochem Photobiol* 1994; 59(3):328-35.
40. Goff BA, Hermanto U, Rumbaugh J, Blake J, Bamberg M, **Hasan T***. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an *in vivo* murine ovarian cancer model. *Brit J Cancer* 1994; 70:474-80.
41. Schmidt-Erfurth U, **Hasan T**, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. *Ophthalmology* 1994; 101:1953-61.
42. Iinuma S, Bachor R, Flotte TJ, **Hasan T**. Biodistribution and phototoxicity of delta amino-levulinic acid-induced PpIX in an orthotopic rat bladder tumor model. *J Urology* 1995; 153:802-06.
43. Bachor R, Hautmann R, **Hasan T**. Comparison of two routes of photosensitizer administration for photodynamic therapy of bladder cancer. *Urological Research* 1994; 22:21-23.
44. Schmidt-Erfurth U, **Hasan T**, Schomacker K, Flotte TJ, Birngruber R. *In vivo* uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. *Lasers Surg Med* 1995; 17:178-88.
45. Aveline BM, **Hasan T***, Redmond RW. The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPD-MA). *J Photochem Photobiol B Biol* 1995; 30:161-69.
46. Hu LK, **Hasan T**, Gragoudas ES, Young LHY. Photoimmunotherapy of human uveal melanoma Cells. *Experimental Eye Research* 1995; 61:385-91.
47. Miller JW, Walsh AW, Kramer M, **Hasan T**, Michaud N, Flotte TJ, Haimovici R, Gragoudas ES. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. *Arch Ophthalmol* 1995; 113:810-18.
48. Schmidt-Erfurth U, Flotte TJ, Gragoudas ES, Schomacker K, Birngruber R, **Hasan T**. Benzoporphyrin-lipoprotein mediated photodestruction of intraocular tumors. *Experimental Eye* 1996; 62:1-10.
49. Cincotta L, Szeto D, Lampros E, **Hasan T**, Cincotta AH. Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. *Photochem Photobiol* 1996; 63(2):229-37.
50. Molpus KL, Kato D, Lilge L, Hamblin MR, Bamberg M, **Hasan T**. Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. *Cancer Res* 1996; 56:1075-82.
51. Gillies R, Kollias N, **Hasan T**, Diddens H. Spectral characterization of the benzoporphyrin derivative monoacid ring-A photoproduct formed in fetal calf solutions during irradiation with 694 nm continuous-wave radiation. *J Photochem Photobiol B Biol* 1996; 33:87-90.
52. Kramer M, Miller JW, Michaud N, Moulton RS, **Hasan T**, Flotte TJ, Gragoudas ES. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy of choroidal neovascularization in monkeys. *Ophthalmology* 1996; 103:427-38.
53. Molpus KL, Koelliker D, Atkins L, Kato D, Buczek-Thomas J, Fuller AF, **Hasan T**. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. *Int J Cancer* 1996; 67:588-95.
54. Hamblin MR, Miller JL, **Hasan T**. Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. *Cancer Res* 1996; 56:5205-10.

55. Goff BA, Blake J, Bamberg MP, **Hasan T**. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. *Brit J Cancer* 1996; 74:1194-98.
56. Schmidt-Erfurth U, Diddens H, Birngruber R, **Hasan T**. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. *Brit J Cancer* 1997; 75(1):54-61.
57. Duska LR, Hamblin MR, Bamberg MP, **Hasan T**. Biodistribution of charged F(ab')₂ photoimmunoconjugates in a xenograft model of ovarian cancer. *Brit J Cancer* 1997; 75(6):837-44.
58. Haimovici R, Kramer M, Miller JW, **Hasan T**, Flotte TJ, Schomacker KT, Gragoudas ES. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. *Curr Eye Res* 1997; 16:83-90.
59. Soukos NS, Hamblin MR, **Hasan T**. The effect of charge on cellular uptake and phototoxicity of polylysine chlorin *e6* conjugates. *Photochem Photobiol* 1997; 65(4):723-29.
60. Pogue BW, **Hasan T**. A theoretical study of light fractionation and dose rate effects in photodynamic therapy. *Radiat Res* 1997; 147:551-59.
61. Pogue BW, **Hasan T**. Fluorophore quantitation in tissue-simulating media with confocal detection. *IEEE Journal of Quantum Electronics* 1996; 959-64.
62. Momma T, Hamblin MR, **Hasan T**. Hormonal modulation of the accumulation of 5-aminolevulinic acid-induced protoporphyrin and phototoxicity in prostate cancer cells. *Int J Cancer* 1997; 72:1062-69.
63. Pogue BW, Lilge L, Patterson MS, Wilson BC, **Hasan T**. Absorbed photodynamic dose from pulsed versus continuous wave light examined with tissue-simulating dosimeters. *Appl Optics* 1997; 36(28):7257-69.
64. Buczek-Thomas JA, Chen N, **Hasan T**. Integrin-mediated adhesion and signalling in ovarian cancer cells. *Cell Signal* 1998; 10(1):55-63.
65. KB, Gandour-Edwards R, Bamberg M, Nishioka NS, Flotte T, Autry S, **Hasan T**. The influence of light delivery on photodynamic synovectomy in an antigen induced arthritis model for rheumatoid arthritis. *Laser Surg Med* 1998; 22:147-56.
66. Van Eps RGS, ChandraSekar NR, **Hasan T**, LaMuraglia GM. Importance of the treatment field for the application of vascular photodynamic therapy to inhibit intimal hyperplasia. *Photochem Photobiol* 1998; 67(3):337-42.
67. Trauner KB, Gandour-Edwards R, Bamberg M, Shortkroff S, Sledge C, **Hasan T**. Photodynamic synovectomy using benzoporphyrin derivative in an antigen-induced arthritis model for rheumatoid arthritis. *Photochem Photobiol* 1998; 67(1):133-39.
68. Ortel B, Brissette J, Chen N, Dotto GP, **Hasan T**. Differentiation-specific increase of ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. *Brit J Cancer* 1998; 77(11):1744-51.
69. Soukos NS, Ximenez-Fyvie LA, Hamblin MR, Socranski SS, **Hasan T**. Targeted antimicrobial photochemotherapy. *Antimicrob Agents Chemo* 1998; 42(10):2595-2601.
70. Lilge L, Molpus K, **Hasan T**, Wilson BC. Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma. *Photochem Photobiol* 1998; 68(3):281-88.
71. Hamblin MR, Bamberg MP, Miller JL, **Hasan T**. Cationic photoimmunoconjugates between monoclonal antibodies and hematoporphyrin: selective photodestruction of ovarian cancer cells. *Applied Optics* 1998; 37(31):7184-92.
72. Momma T, Hamblin MR, Wu HC, **Hasan T**. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. *Cancer Res* 1998; 58:5425-31.

73. Pogue BW, Redmond RW, Trivedi N, **Hasan T**. Photophysical properties of tin ethyl etiopurpurin 1 (SNET2) and tin octaethylbenzochlorin (SnOEBC) in solution and bound to albumin. *Photochem Photobiol* 1998; 68(6):809-15.
74. Pogue BW, Momma T, Wu HC, **Hasan T**. Transient absorption changes *in vivo* during photodynamic therapy with pulsed-laser light. *Brit J Cancer* 1999; 80(3/4): 344-51.
75. Runnels JM, Chen N, Ortel B, Kato D, **Hasan T**. BPD-MA-mediated photosensitization *in vitro* and *in vivo*: cellular adhesion and β_1 integrin expression in ovarian cancer cells. *Brit J Cancer* 1999; 80:946-53.
76. Hamblin MR, Rajadhyaksha M, Momma T, Soukos NS and **Hasan T**. *In vivo* fluorescence imaging of the transport of charged chlorin *e6* conjugates in a rat orthotopic prostate cancer. *Brit J Cancer* 1999; 81(2):261-68.
77. Duska LR, Hamblin MR, Miller JL, **Hasan T**. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer *ex vivo*. *J Nat Cancer* 1999; 91(18):1557-63.
78. Khadem J, Velose AA, Tolentino, F, **Hasan T**, Hamblin M. Photodynamic tissue adhesion with Chlorin *e6* protein conjugates. *Invest Ophtha Vis Sci* 1999; 40:3132-37.
79. Iinuma S, Schomacker KT, Wagnieres G, Rajadhyaksha M, Bamberg M, Momma T, **Hasan T**. *In vivo* fluence rate and fractionation effects on tumor response and photobleaching in photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. *Cancer Res* 1999; 59(24):6164-70.
80. Del Governatore M, Hamblin MR, Piccinini EE, Ugolina G, **Hasan T**. Targeted photodestruction of human colon cancer cells using charged 17.1A chlorin *e6* immunoconjugates. *Br J Cancer* 2000; 82(1):56-64.
81. Lein M, Ortel B, Koenig F, Misdraji J, McDougal WS, Jung K, Loening SA, **Hasan T**. Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation. *J Urology* 2000; 56(1):167-72.
82. Molpus KL, Hamblin MR, Rizvi I, **Hasan T**. Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. *Gynecol Oncol* 2000; 76(3):397-404.
83. Del Governatore M, Hamblin M, Shea C, Rizvi I, Molpus K, Tanabe K, **Hasan T**. Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin *e6* immunoconjugate. *Cancer Res* 2000; 60(15):4200-5.
84. Lein M, Jung K, Le D, **Hasan T**, Ortel B, Bochert D, Giessing M, Schnorr D, Loening S. Synthetic inhibitor of matrix metalloproteinases (Batimastat) reduces prostate cancer growth in a orthotopic rat model. *Prostate* 2000;43(2):77-82.
85. Hamblin MR, Del Governatore M, Rizvi I, **Hasan T**. Biodistribution of charged 17.1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer. *Br J Cancer* 2000; 83(11):1544-51.
86. Pogue BW, Ortel B, Chen N, Redmond RW, **Hasan T**. A photobiological and photophysical-based study of phototoxicity of two chlorins. *Cancer Res* 2001; 62(2):717-24.
87. Heitner T, Moor ACE, Garrison JL, Marks C, **Hasan T**, Marks JD. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. *J Immunol Methods* 2001; 248:17-30.
88. Soukos NS, Hamblin MR, Keel S, Fabian RL, Deutsch TF, **Hasan T**. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer *in vivo*. *Cancer Res* 2001; 61(11):4490-6.
89. Hamblin MR, Miller JL, Rizvi I, Ortel B, Maytin EV, **Hasan T**. Pegylation of a chlorin *e6* polymer conjugate increases tumor targeting of a photosensitizer. *Cancer Res* 2001; 61(19):7155-62.

90. Sullivan LG, **Hasan T**, Wright M, Mankin HJ, Towle CA. Photodynamic treatment has chondroprotective effects on articular cartilage. *J Orthop Res* 2002; 20(2):241-8.
91. Hamblin MR, O'Donnell DA, Murthy N, Contag CH, **Hasan T**. Rapid control of wound infections by targeted photodynamic therapy monitored by *in vivo* bioluminescence imaging. *Photochem Photobiol* 2002; 75(1):51-57.
92. Haimovici R, Ciulla T, Miller J, **Hasan T**, Flotte T, Kenney AG, Schomacker KT, T, Gragoudas ES. Localization of rose bengal, aluminum phthalocyanine tetrasulfonate, and chlorin E₆ in the rabbit eye. *Retina* 2002; 22(1):65-74.
93. Duska LR, Wimberly J, Deutsch TF, Ortel B, Haas J, Houck K, **Hasan T**. Detection of female lower genital tract dysplasia using orally administered aminolevulinic acid induced protoporphyrin IX: a preliminary study. *Gynecol Oncol* 2002; 85(1):125-8.
94. Hamblin MR, O'Donnell DA, Murthy N, Rajagopalan K, Michaud N, Sherwood ME, **Hasan T**. Polycationic photosensitizer conjugates: effects of chain length and Gram classification on the photodynamic inactivation of bacteria. *J Antimicrob Chemother* 2002; 49(6):941-51.
95. Ortel B, Sharlin D, O'Donnell D, Sinha AK, Maytin EV, **Hasan T**. Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. *Br J Cancer* 2002; 87(11):1321-7.
96. Jung K, Krell HW, Ortel B, **Hasan T**, Romer A, Schnorr D, Loening SA, Lein M. Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats. *Prostate* 2003; 54(3):206-11.
97. Pogue BW, O'Hara JA, Demidenko E, Wilmot CM, Goodwin IA, Chen B, Swartz HM, **Hasan T**. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. *Cancer Res* 2003; 63(5):1025-33.
98. Savellano M, **Hasan T**. Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. *Photochem Photobiol* 2003; 77(4):431-9.
99. Hamblin MR, Zahra T, Contag CH, McManus AT, **Hasan T**. Optical monitoring and treatment of potentially lethal wound infections *in vivo*. *J Infect Dis* 2003; 187(11):1717-25.
100. Hamblin MR, Miller JL, Rizvi I, Loew HG, **Hasan T**. Pegylation of charged polymer-photosensitizer conjugates: effects on photodynamic efficacy. *Br J Cancer* 2003; 89(5):937-43.
101. Chen B, Pogue BW, Goodwin IA, O'Hara JA, Wilmot CM, Hutchins JE, Hoopes PJ, **Hasan T**. Blood flow dynamics following photodynamic therapy with verteporfin in the RIF-1 tumor. *Radiat Res* 2003 Oct; 160(4):452-9.
102. Gad F, Zahra T, Francis K, **Hasan T**, Hamblin MR. Targeted photodynamic therapy of established soft-tissue in mice. *Photochem Photobiol Sci* 2004; 3(5):451-8.
103. Zhou X, Pogue BW, Chen B, **Hasan, T**. Analysis of effective molecular diffusion rates for verteporfin in subcutaneous versus orthotopic Dunning prostate tumors. *Photochem Photobiol* 2004; 79(4): 323-31.
104. Gad F, Zahra T, Khan Z, **Hasan T**, Hamblin MR. Effects of growth phase and extracellular slime on photodynamic inactivation of gram-positive pathogenic bacteria. *Antimicrob Agents Chemother* 2004; 48(6):2173-8.
105. Georgakoudi I, Solban N, Novak J, Rice WL, Wei X, **Hasan T**, Lin CP. *In vivo* flow cytometry: a new method for enumerating circulating cancer cells. *Cancer Res* 2004; 64(15): 5044-7.
106. Chen B, Pogue BW, Hoopes PJ, **Hasan T**. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. *Int J Radiat Oncol Biol Phys* 2005; 61(4): 1216-26.
107. Chen B, Pogue BW, Zhou X, O'Hara JA, Solban N, Demidenko E, Hoopes PJ, **Hasan T**. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. *Clin Cancer Res* 2005; 11(2): 720-7.

108. Lambrechts SA, Demidova TN, Aalders MC, **Hasan T**, Hamblin MR. Photodynamic therapy for *Staphylococcus aureus* infected burn wounds in mice. *Photochem Photobiol* 2005;4:503-9.
109. Savellano M, **Hasan T**. Photochemical targeting of epidermal growth factor receptor: a mechanistic study. *Clin Cancer Res* 2005; 11(4): 1658-68.
110. Del Carmen MG, Rizvi I, Chang Y, Moor AC, Oliva E, Sherwood M, Pogue B, **Hasan T**. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. *J Natl Cancer Inst* 2005; 97(20):1516-24.
111. Chen B, Pogue BW, Luna JM, Hardman RL, Hoopes PJ, **Hasan T**. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism and therapeutic implications. *Clin Cancer Res* 2006;12(3):917-23.
112. Kosaka S, Kawana Seiji, Zouboulis C, **Hasan T**, Ortel B. Targeting of sebocytes by aminolevulinic acid-dependent photosensitization. *Photochem Photobiol* 2006; 82(2):453-7.
113. Zhou X, Pogue BW, Chen B, Demidenko E, Joshi R, Hoopes J, **Hasan T**. Pretreatment photosensitizer dosimetry reduces variation in tumor response. *Intl J of Rad Onc* 2006; 64(4):1211-20.
114. O’Riordan K, Sharlin DS, Gross J, Chang S, Errabelli D, Akilov OE, Kosaka S, Nau GJ, **Hasan T**. Photoinactivation of mycobacteria *in vitro* and in a new murine model of localized mycobacterium bovis BCG-induced granulomatous infection. *Antimicrob Agents Chemother* 2006, 50(5), 1828-34.
115. Solban N, Selbo PK, Sinha AK, Chang SK, **Hasan T**. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. *Cancer Res* 2006 Jun 1;66(11):5633-40.
116. Solban N, Rizvi I, **Hasan T**. Targeted photodynamic therapy. *Lasers Surg Med* 2006 Jun;38(5):522-31.
117. Gibbs SL, Chen B, O'hara JA, Hoopes PJ, **Hasan T**, Pogue BW. Protoporphyrin IX Level Correlates with Number of Mitochondria, but Increases in Production Correlate with Tumor Cell Size. *Photochem Photobiol* 2006 Mar 1; [Epub ahead of print].
118. Casas A, Perotti C, Ortel B, Di Venosa G, Saccoliti M, Batlle A, **Hasan T**. Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving cells. *Int J Oncol* 2006 Aug;29(20):397-405.
119. Akilov OE, Kosaka S, O’Riordan K, Song X, Sherwood M, Flotte TJ, Foley JW, **Hasan T**. The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against *Leishmania* parasites. *Chem & Biol* 2006 Aug; 13, 839-847.
120. Sato N, Moore B, Keevey S, Drazba J, **Hasan T**, Maytin EV. Vitamin D enhances ALA-mediated protoporphyrin IX production and photodynamic cell death in 3-D organotypic cultures of keratinocytes. *J Invest Dermatol* 2006 Oct 19; [Epub ahead of print].
121. Yelin D, Rizvi I, White WM, Motz JT, **Hasan T**, Bouma BE, Tearney GJ. Three-dimensional miniature endoscopy. *Nature* 2006, Oct 443; 19.
122. Sinha AK, Anand S, Ortel BJ, Chang Y, Mai Z, **Hasan T**, Maytin EV. Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. *Brit J Cancer* 2006 Aug 21;95:485-495.
123. Kosharskyy B, Solban N, Chang SK, Rizvi I, Chang Y, **Hasan T**. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. *Cancer Res* 2006 Nov 15;66(22):10953-8.
124. Zhou X, Chen B, Hoopes PJ, **Hasan T**, Pogue BW. Tumor Vascular area correlates with photosensitizer uptake; analysis of verteporfin microvascular delivery in the dunning rat prostate tumor. *Photochem Photobiol* 2006 Sep-Oct;82(5):1348-57.
125. Akilov OE, Khachemoune A, **Hasan T**. Clinical manifestations and classification of Old World cutaneous leishmaniasis. *Int J Dermatol* 2007; 46:132-42.
126. Kosaka S, Akilov OE, O’Riordan K, **Hasan T**. A Mechanistic Study of delta-Aminolevulinic Acid-Based Photodynamic Therapy for Cutaneous Leishmaniasis. *J Invest Dermatol* 2007, 127(6):1546-1549.

127. Akilov OE, Kosaka S, O'Riordan K, **Hasan T**. Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. *Exp Dermatol*. 2007 Aug;16(8):651-60.
128. Sheng C, Hoopes PJ, **Hasan T**, Pogue BW. Photobleaching-based dosimetry predicts deposited dose in ALA-PpIX PDT of rodent esophagus. *Photochem Photobiol*. 2007 May-Jun;83(3):738-48.
129. Akilov OE, Donovan MJ, Stepinac T, Carter CR, Whitcomb JP, **Hasan T**, McDowell MA. T helper type 1 cytokines and keratinocyte growth factor play a critical role in pseudoepitheliomatous hyperplasia initiation during cutaneous leishmaniasis. *Arch Dermatol Res*. 2007 Sep;299(7):315-25.
130. Zhou X, Chen B, Hoopes PJ, **Hasan T**, Pogue BW. Peptide-induced inflammatory increase in vascular permeability improves photosensitizer delivery and intersubject photodynamic treatment efficacy. *Radiat Res*. 2007 Sep; 168(3):299-307.
131. O'riordan K, Akilov OE, Chang SK, Foley JW, Hasan T. Real-time fluorescence monitoring of phenothiazinium photosensitizers and their anti-mycobacterial photodynamic activity against *Mycobacterium bovis* BCG in in vitro and in vivo models of localized infection. *Photochem Photobiol Sci*. 2007 Oct;6(10):1117-23.
132. Akilov OE, Kosaka S, O'riordan K, Hasan T. Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation. *Photochem Photobiol Sci*. 2007 Oct;6(10):1067-75.
133. Sato N, Moore BW, Keevey S, Drazba JA, Hasan T, Maytin EV. Vitamin D enhances ALA-induced protoporphyrin IX production and photodynamic cell death in 3-D organotypic cultures of keratinocytes. *J Invest Dermatol* 2007; 127(4):925-34.
134. Styer AK, Sullivan BT, Puder M, Arsenault D, Petrozza JC, Serikawa T, Chang S, Hasan T, Gonzalez RR, Rueda BR. Ablation of leptin signaling disrupts the establishment, development and maintenance of endometriosis-like lesions in a murine model. *Endocrinology* 2008, 149 (2):506-514.
135. Waisbren SE, Bowles H, Hasan T, Zou KH, Emans SJ, Goldberg C, Gould S, Levine D, Lieberman E, Loeken M, Longtine J, Nadelson C, Patenaude AF, Quinn D, Randolph AG, Solet JM, Ullrich N, Walensky R, Weitzman P, Christou H. Gender Differences in Research Grant Applications and Funding Outcomes for Medical School Faculty. *Journal of Women's Health*, 2008; 17 (2): 207-214.
136. Lee S, Zhu L, Minhaj AM, Hinds MF, Vu DH, Rosen DI, Davis SJ, Hasan T. Pulsed diode laser-based monitor for singlet molecular oxygen. *J Biomed Opt*. 2008 May-Jun;13(3):034010.
137. Styer AK, Sullivan BT, Puder M, Arsenault D, Petrozza JC, Serikawa T, Chang S, Hasan T, Gonzalez RR, Rueda BR. Ablation of leptin signaling disrupts the establishment, development and maintenance of endometriosis-like lesions in a murine model. *Endocrinology* 2008, 149 (2):506-514.
138. Verma S, Sallum UW, Athar H, Rosenblum L, Foley JW, Hasan T. Antimicrobial Photodynamic Efficacy of Side-chain Functionalized Benzo[a]phenothiazinium Dyes. *Photochem Photobiol*. 2008 Jul 23. [Epub ahead of print]
139. Casas A, Venosa GD, Vanzulli S, Perotti C, Mamome L, Rodriguez L, Simian M, Juarranz A, Pontiggia O, Hasan T, Batlle A. Decreased metastatic phenotype in cells resistant to aminolevulinic acid-photodynamic therapy. *Cancer Lett*. 2008 Jul 26. [Epub ahead of print]
140. Pogue, Brian W.; Sheng, Chao; Benevides, Juan; Forcione, David; Puricelli, Bill; Nishioka, Norm; Hasan, Tayyaba. Protoporphyrin IX fluorescence photobleaching increases with the use of fractionated irradiation in the esophagus. *Journal of Biomedical Optics* (2008), 13(3), 034009/1-034009/10.

141. Chang, Sung K.; Rizvi, Imran; Solban, Nicolas; Hasan, Tayyaba. In vivo Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment. *Clinical Cancer Research* (2008), 14(13), 4146-4153.

Full Proceedings of Meetings:

1. **Hasan T**, Ed. Advances in photochemotherapy. SPIE Proceedings; 1988; SPIE Publishers Vol. 997, 1988.
2. Latina M, Kobsa P, Rakestraw SL, Yarmush MY, **Hasan T**. Photochemical targeting of phagocytic trabecular meshwork cells with chlorin e6 coupled microspheres. *Advances in Photochemotherapy. SPIE Proc*, 997, 32-41, 1989.
3. **Hasan T**. Selective phototoxicity using monoclonal antibody-chromophore conjugates. *Advances in Photochemotherapy. SPIE Proc* 1989;997, 42-7.
4. **Hasan T**. Chen N, Anderson T, Deak MR, Linden K, Granstein R, Zurawki VR, Flotte T. Immunologic targeting of cancer cells. *Fundamentals of Photodynamic Therapy. SPIE Proc* 1989;1065(11):80-6.
5. Shea CR, Sherwood M, Flotte TJ, **Hasan T**. Structural and functional alterations in R123-and doxycycline-photosensitized cells. *SPIE Proc*, 1202:80-83, 1990.
6. **Hasan T**. Cellular response of ovarian carcinoma cells to antibody-photosensitizer-mediated injury. *SPIE Proc* 1990;1203:126-36.
7. Ortu P, LaMuraglia G, Roberts G, Flotte T, **Hasan T**, Abbott W. Inhibition of intimal hyperplasia using photodynamic therapy. *Surgical Forum* 1991;Vol. XLII:340-42.
8. LaMuraglia GM, Ortu P, Roberts WG, Flotte TJ, **Hasan T**. Photodynamic application on arteries. 3rd World Congress International Society for Low Power Laser Applications in Medicine. *Laser Bologna '92, Bologna, Italy*, 439-444, September 1992.
9. Goff BA, Bamberg MP, **Hasan T**. Experimental photodynamic treatment of ovarian cancer cells with immunoconjugates. *Antibody, Immunoconjugates, and Radiopharmaceuticals*. 5(2):191-99, 1992.
10. Flotte TJ, Anderson T, McAuliffe DJ, **Hasan T**, Doukas A. Laser-induced enhancement of drug cytotoxicity: a new approach to cancer therapy. *SPIE Proc* 1882:122-129, 1993.
11. Lilge L, Dabrowski W, Holdsworth DW, Blake J, Kato D, Wilson BC, **Hasan T**. Light delivery and dosimetry for photodynamic therapy in an ovarian cancer mouse model. *Proc SPIE* 2133:150-61, 1994.
12. Diddens H, Gillies R, **Hasan T**. In vitro photosensitizing activity of BPD-MA using pulsed and continuous wave radiation. In: *Photodynamic Therapy of Cancer. Euro SPIE Proc* 2078, 212-218, 1994.
13. Diddens H, Gillies R, **Hasan T**. Comparison of high-intensity pulsed and continuous wave irradiation on benzoporphyrin derivative-induced photosensitization of bladder cancer cells. In: *Laser-Tissue Interaction V. SPIE Proc* 2134:210-215, 1994.
14. Iinuma S, Wagnieres G, Schomacker KT, Bamberg M, **Hasan T**. The importance of fluence rate in photodynamic therapy with ALA-induced PpIX and BPD-MA in a rat bladder tumor model. *SPIE Proc*, Vol. 2392, 136-140, 1995.
15. Iinuma S, Wagnieres G, Schomacker KT, Bamberg M, **Hasan T**. Comparison of photobleaching and fluence rate effects in PpIX and BPD-MA photosensitization of rat bladder tumor in vivo. *SPIE Proc*, Vol. 2391, 225-231, 1995.
16. Pogue BW, Redmond RW, **Hasan T**. A study of dosimetry for pulsed-laser photodynamic therapy. *Proc SPIE, Laser Tissue Interaction VII*, 2681, 275-284, 1996.
17. Pogue BW, Lilge L, Zhang K, Wilson BC, Redmond RW, **Hasan T**. Measurement of the triplet state yield of photosensitizers in scattering media. *Proc SPIE, Optical Methods for Tumor*

- Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy VI, Vol 2972, 168-172, 1997.
18. Pogue BW, **Hasan T.** Quantitative fluorescence measurements from tissue using confocal detection. Proc SPIE, Laser-Tissue Interaction VIII, Vol 2975, 202-207, 1997.
 19. Pogue BW, Chen N, Luedemann H-C, Redmond RW and **Hasan T.** Comparative measurement of photosensitizer triplet yields in vitro. Trends in Optics and Photonics, Therapeutic Laser Applications. (Ed: M.N. Ediger), Vol. XXII, 216-219, 1998.
 20. Pogue BW, O'Hara JA, Liu KJ, **Hasan T.**, Swartz H. Photodynamic treatment of the RIF-1 tumor with verteporfin with online monitoring of tissue oxygen using electron paramagnetic resonance oximetry. Proc SPIE, Laser-Tissue Interaction X. Eds. Steven L. Jacques; Gerhard J. Mueller, A. Roggan; D. H. Sliney. Vol 3601, 08-114, 1999.
 21. Moor ACE, Hamblin MR, Molpus K, Duska L, Rizvi I. **Hasan T.** Photoimmunotherapy of ovarian cancer. In: Optical methods for tumor treatment and detection: Mechanisms and Techniques in Photodynamic therapy IX. Eds Dougherty T. and Hasan T. SPIE Proceedings 3909, 30-33, 2000.
 22. Soukos NS, Hamblin MR, Deutsch TF, **Hasan T.** Monoclonal antibody-tagged receptor-targeted contrast agents for detection of cancers, Proc SPIE, 4259, 115-128, 2001.
 23. Hamblin MR, O'Donnell DA, Zahra T, Contag CH, McManus AT, and **Hasan T.** Targeted photodynamic therapy for infected wounds in mice. Proc SPIE, 4612, 48-57, 2002.
 24. Pogue BW, O'Hara JA, Demidenko E, Wilmot CM, Chen B, Swartz, HM, **Hasan T.** Increasing oxygenation and radiation sensitivity following photodynamic therapy with verteporfin in the RIF-1 tumor. Proc SPIE, 4952-8, 2003.
 25. Chen B, Pogue BW, Goodwin IA, O'Hara JA, Wilmot CM, Hutchins JE, Hoopes PJ, **Hasan T.** Effect of photodynamic therapy with Verteporfin on tumor blood flow. Proc SPIE, 2952-10, 2003.
 26. Davis SJ, Zhu L, Minhaj AM, Hinds MF, Lee S, Keating PB, Rosen, DI, and **Hasan T.** Ultra-sensitive, diode-laser-based monitor for singlet oxygen. Proc SPIE, 4952-24, 2003.
 27. Zhou X, Pogue BW, Nishioka NS, Puricelli B, **Hasan T.** Light dosimetry for photodynamic therapy in the esophagus. Proc SPIE, 4952-30, 2003.
 28. Solban N, Georgakoudi I, Rice W, Lin C, **Hasan T.** Role of cell type and animal species in tumor metastasis, Proc SPIE, 5315, 41-48, 2004.
 29. Gad F, Zahra T, **Hasan T.**, Hamblin MR. Targeted photodynamic therapy of established soft-tissue infections in mice, Proc SPIE, 5315, 65-75, 2004.
 30. Solban N, Georgakoudi I, Ortel B, Lin C, **Hasan T.** Optical imaging in photodynamic therapy: mechanisms and applications, Proc SPIE, 5329, 192-200, 2004.
 31. **Hasan T.**, Solban N. Photochemical effects in laser-tissue interactions: photodynamic therapy, an overview. Proc SPIE, 5319, 41-49, 2004.
 32. Solban N, Sznycer-Taub N, Benavides JM, Chang S, Georgakoudi I, **Hasan T.** The need for optical imaging in the understanding and optimization of photodynamic therapy. Proc SPIE, 5704, 1-9, 2005.
 33. Lee S, Zhu L, Minhaj A, Hinds M, Ferrante AA, Vu DH, Rosen D, Davis SJ, **Hasan T.** Diode laser monitor for singlet molecular oxygen. Proc SPIE , 5689, 90-96, 2005.
 34. Chang SK, Rizvi I, Solban N, **Hasan T.** In Vivo Imaging of VEGF Expression for Monitoring Molecular Response to Cancer Therapy. OSA Biomedical Optics Technical Digest 2006; TuC4.
 35. Chang SK, Errabelli D, Rizvi I, Solban N, O'Riordan K, **Hasan T.** Molecular imaging of photodynamic therapy. Proc SPIE, 6449, 644902, 2007.
 36. Gibbs-Strauss, Summer L.; Davis, Scott C.; O'Hara, Julia A.; Hoopes, P. Jack; Hasan, Tayyaba; Pogue, Brian W. Noninvasive murine glioma detection improved following photobleaching of skin PpIX fluorescence. Proc SPIE (2008), 6845(Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XVII), 68450D/1-68450D/9.

Reviews:

1. **Hasan T**: Photodynamic Therapy: A Review of Current Status and Future Directions. In: S. Davis, (ed.) Critical Reviews in Oncology/Hematology. [Invited Review]
2. Cooperman BS, Kerlavage AR, **Hasan T**, Weizman C, Cannon M, Smith J: Utilization of HPLC in Studies of Ribosomes and Their Antibiotic Inhibitors. Bio Techniques, 1985.
3. Schmidt U, Birngruber R, **Hasan T**. Selektiver Verschluss okulärer Neovaskularisationen durch photodynamische Therapie (PDT). Ophthalmologie 1992;89:391-94.
4. Ortu P, LaMuraglia GM, Roberts WG, Schomacker KT, Deutsch TF, Flotte TJ, **Hasan T**: Treatment of arterial intimal hyperplasia with photodynamic therapy. Photodynamic Therapy & Biomedical Lasers, 1992:225-232.
5. Ortel B, Calzavara-Pinton PG, Szeimies, **Hasan T**: Perspectives in cutaneous photodynamic sensitization. J Photochem Photobiol B: Biol, 1996:36:209-211.
6. Hamblin M, **Hasan T**. Photodynamic Therapy: An Overview. Optics & Photonics News, 1996:17-21.
7. Trauner KB, **Hasan T**. Photodynamic Treatment of Rheumatoid and Inflammatory Arthritis. J Levy (ed.). Photochem Photobiol "Symposium-in-Print" 1996:64(5), 740-750.
8. Schmidt-Erfurth U, Birngruber R, **Hasan T**. Photodynamic therapy in ocular vascular disease. J Quantum Electronics 1997;988-96.
9. Ortel B, Farshi-Ortel SS, **Hasan T**. Photodynamic therapy in dermatology. Dermatología & Cosmética 1997;265-72.
10. Birngruber R, Schmidt-Erfurth U, **Hasan T**. Photodynamic therapy on age-related macular degeneration. Laser Opto 2: 2000;66-70.
11. Schmidt-Erfurth U, **Hasan T**. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Survey of Ophthalmology 2000;45:195-214.
12. Pogue B, **Hasan T**. Targeting in photodynamic therapy and photo-imaging, Optics & Photonics News 2003;14(8):36-43.
13. Hamblin M, **Hasan T**. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobio Sci 2004;3,436-450.
14. Chen B, Pogue BW, **Hasan T**. Liposomal delivery of photosensitizing agents. Expert Opin Drug Deliv 2005;2(3):477-87.
15. O'Riordan K, Akilov O, **Hasan T**. The potential for photodynamic therapy in the treatment of localized infections. Photodiagnosis and Photodynamic Therapy 2005; 2(4), 247-62.
16. Solban N, Rizvi I, **Hasan, T**. Targeted photodynamic therapy. Lasers Surg Med 2006 May 2; [Epub ahead of print].
17. O'Riordan K, Sharlin DS, Gross J, Chang S, Errabelli D, Akilov OE, Kosaka S, Nau GJ, **Hasan T**. Photoinactivation of *Mycobacteria* in vitro and in a new murine model of localized *Mycobacterium bovis* BCG-induced granulomatous infection. Antimicrob Agents Chemother. 2006; 50(5):1828-34.
18. Akilov OE, Kosaka S, O'Riordan K, Song X, Sherwood M, Flotte TJ, Foley JW, **Hasan T**. The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against *Leishmania* parasites. Chemistry and Biology 2006; 13 (8): 839-847.
19. Akilov OE, Khachemoune A, **Hasan T**. Clinical manifestations and classification of Old World cutaneous leishmaniasis. Int J Dermatol 2006; 45 (11) (in press).
20. Chen B, Pogue BW, Hoopes JP, **Hasan T**. Vascular and Cellular Targeting for Photodynamic Therapy. Critical Reviews in Eukaryotic Gene Expression 2006; 16 (4) 279-305.
21. Verma S, Watt G M, Mai Z, **Hasan T**. Strategies for Enhanced Photodynamic Therapy Effects. Photochem Photobiol 2007, 83(5):996-1005.

- Akilov OE, Kosaka S, Maytin EV, Hasan T. Prospects for the use of differentiation-modulating agents as adjuvant of photodynamic therapy for proliferative dermatoses. *J Dermatol.* 2008 Apr;35(4):197-205.

Book Chapters:

- Fry A, Sims LB, Eubanks JRI, **Hasan T**, Kanski R, Pettigrew FA, Crook S: Carbon-14 isotope effect studies of mechanisms of some elimination reactions. In: International symposium on synthesis and applications of isotopically labeled compounds. Elsevier Scientific Publishing Co. 133-138, 1983.
- McAuliffe DJ, **Hasan T**, Kochevar IE, Parrish JA: An *in vitro* test for predicting the photosensitizing potential (PSP) of various chemicals. In: Goldberg AM, editor. Alternative methods in toxicology, Mary Ann Liebert, Inc., New York, 3:29-42, 1985.
- Cooperman BS, Hall CC, Kerlavage AR, Weitzman C, **Hasan T**, Smith J, Friedlander J: Photoaffinity labeling of *Escherichia coli* ribosomes. New approaches and results in structure, function and genetics of ribosomes. In: Hardesty B, Kramer G, editors. Springer Verlag, New York, 1986:362-376.
- Hasan T**: Photosensitizer delivery mediated by macromolecular carrier systems. In: B. Henderson and T. Dougherty (eds.). Photodynamic therapy: basic principles and clinical applications. Marcel Dekker, 1992; p.187-200.
- Wagnieres GA, Iinuma S, Schomacker K, Deutsch T, **Hasan T**. In vivo Tissue Characterisation Using Environmentally Sensitive Fluorochromes. In: Slavik J, editor. Fluorescence microscopy and fluorescent probes. Plenum Publishing Corporation, New York, NY, 1996.
- Hasan T**. Intra-Abdominal Photodynamic Therapy. In: Piccinini E, editor. New perspectives in the treatment of malignant tumors. Bologna, Italy: Cooperative Universitaria Studio e Lavoro a.r.l., 1996; p.35-48.
- Hasan T**, Parrish JA: Photodynamic therapy of cancer. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, and Weichselbaum RR, editors. Cancer Medicine. 4th ed. Baltimore: Williams & Wilkins, 1997; p.739-51.
- Hasan T**, Moor A, Ortel B. Photodynamic therapy of cancer. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, and Weichselbaum RR, editors. Cancer Medicine. 5th ed. Hamilton, Ontario: B.C. Decker, Inc., 2000. p. 489-502.
- Hasan T**, Ortel B, Moor A, Pogue B. Photodynamic therapy of cancer. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, and Frei E III, editors. Cancer Medicine 6th ed. Hamilton, Ontario: B.C. Decker, Inc., 2003. p. 605-22.
- Moor A, Ortel B, **Hasan T**. Mechanisms of photodynamic therapy. In: T. Patrice, editor. Photodynamic therapy. Cambridge: The Royal Society of Chemistry, 2003. p.19-57.
- Solban N, Ortel B, Pogue B, **Hasan T**. Targeted optical imaging and photodynamic therapy. In: Bogdanov AA Jr, Licha K, editors. Molecular imaging: an essential tool in preclinical research, diagnostic imaging, and therapy. Heidelberg: Springer-Verlag; 2005. p. 229-58.
- Hasan T**, Ortel B, Solban N, Pogue B. Photodynamic therapy of cancer. In: Kufe DW, Bast RC Jr, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, and Frei E III, editors. Cancer Medicine 7th ed. Hamilton, Ontario: B.C. Decker, Inc., 2006. p. 537-48.

Patents:

- Trauner K, **Hasan T**, Hamblin M, inventors; Massachusetts General Hospital assignee. Inhibition of fibrosis by photodynamic therapy. U.S. Patent No. 5,913,884. 1999 Jun 22.
- Hasan T**, Trauner K, Hamblin M, inventors; Massachusetts General Hospital assignee. Acceleration of Wound Healing by Photodynamic Therapy. U.S. Patent No. 6,107,466. 2000 Aug 22.

3. Levy J, Miller JW, Gradoudas ES, **Hasan T**, Schmidt-Erfurth, U. inventors; Massachusetts General Hospital assignee. Use of green porphyrins to treat neovasculature in the eye. U.S. Patent No. 5,707,986. 1998 January 13.
4. Trauner K, **Hasan T**, inventors; Massachusetts General Hospital assignee. Photodynamic therapy for the destruction of the synovium in the treatment of rheumatoid arthritis and the inflammatory arthritides. U.S. Patent No. 5,368,841. 1994 Nov 29.
5. Cincotta A, Cincotta L, **Hasan T**, inventors; Massachusetts General Hospital, Rowland Institute for Science assignees. Benzophenothiazine and Benzoporphyrin Dye Combination Photodynamic Therapy of Tumors. U.S. Patent No. 5,952,329. 1999 Sep 14.
6. Trauner K, **Hasan T**, inventors; Massachusetts General Hospital assignee. Photodynamic Therapy for the Treatment of Osteoarthritis. U.S. Patent No. 5,942,534. 1999 Aug 24.
7. **Hasan T**, Hamblin M, Soukos N, inventors; Massachusetts General Hospital assignee. Photosensitizer Conjugates for Pathogen Targeting. U.S. Patent No. 7,268,155. 2007 Sept 11.
8. **Hasan T**, Gross J, Nau G, inventors; Massachusetts General Hospital assignee. Photosensitizer Conjugates for Targeting Intracellular Pathogens. U.S. Patent No. 6,977,075. 2005 Dec 20.
9. **Hasan T**, Savellano M, Skobe M, inventors; Massachusetts General Hospital assignee. Photoimmunotherapies for Cancer using Photosensitizer Immunoconjugates and Combination Therapies. U.S. Patent App No. 20020197262. Pending
10. Hasan T, Ortel B, Maytin E, inventors, Massachusetts General Hospital assignee. Treatment and Analysis of Proliferative Disorders. U.S. Patent App No. 20040228871. Pending.
11. Fishman A, Hamblin M, Tawakol A, Hasan T, Muller J, Anderson T, Elmaleh D, Gewirtz H, Massachusetts General Hospital assignee. Detection and therapy of vulnerable plaque with fluorescent and/or radiolabeled compositions. U.S. Patent App No. 20030082105.
12. Pogue B, O'Hara J, Swartz H, Hasan T, Massachusetts General Hospital assignee. Methods of Adjuvant Photodynamic Therapy to enhance Radiation Sensitizer U.S. Patent App No. 20050112131. Pending.
13. Hasan T, Massachusetts General Hospital assignee. Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof. U.S. Patent App No. 20070020272. Pending.
14. Hasan T, Nau G, Aveline B, Massachusetts General Hospital assignee. Activatable Antimicrobial Agents. U.S. Patent App Serial No. 60/736,917. Pending.
15. Hasan T, Massachusetts General Hospital assignee. Use of Nanotechnology & PDT to Treat Diseases. U.S. Patent App Serial No. 11/921,597. Pending.
16. Tearney G, Bouma B, Hasan T, Verma S, Peng L, Massachusetts General Hospital assignee. Methods and Devices for Multidimensional Multiplexed Luminescence Imaging and Diagnosis. U.S. Patent App Serial No. 12/016,051. Pending.
17. Hasan T, Verma S, Sallum U, Zheng X, Massachusetts General Hospital assignee. Fluorescent Substrates for the Detection of Bacterial Virulence Enzymes. Provisional Filing Pending.

Abstracts (partial listing out of more than 200):

1. Metz KR, Bowers JL, Hermanto U, Roberts WG, **Hasan T**. Assessment of tumor response to photodynamic therapy using 31P one-dimensional chemical shift imaging. 17th L.H. Gray Conference, University of Kent at Canterbury, UK, April 1992.
2. Runnels J, **Hasan T**. The protective role of metallothioneins (MTs) in UVB and benzoporphyrin (BPD) phototoxicity. American Association for Cancer Research, Orlando, FL, May 1993.
3. **Hasan T**. Oxidative damage in PDT-treated cells. American Society for Photobiology, Chicago, IL, June 1993.
4. **Hasan T**. Cellular responses in photosensitization: Effects of differentiation and alterations in cell

- adhesion. BiOS '95, Barcelona, Spain, September 1995.
5. Buczek-Thomas J, **Hasan T**. Integrin-mediated signal transduction in ovarian cancer cell lines. American Association for Cancer Research Conference, Washington, D.C., April 1996.
 6. Del Governatore M, Hamblin MR, Tanabe K, Piccinini E, Ugolini G, **Hasan T**. Targeting hepatic metastases of colorectal cancer by charged photoimmunoconjugates. 12th International Congress on Photobiology, Vienna, Austria, September 1996.
 7. Hamblin MR, Rajadhyaksha M, Momma T, **Hasan T**. The effect of size and charge on the localization of photosensitizer conjugates in a tumor model. Biomedical Engineering Society 1996 Annual Fall Meeting, University Park, PA, October 1996.
 8. Molpus K, Hamblin M, Bamberg M, **Hasan T**. Intraperitoneal photoimmunotherapy of human ovarian carcinoma in a xenograft model using charged conjugates. NEAGO Annual Meeting, New Haven, CT, June 1996.
 9. Hamblin MR, Momma T, **Hasan T**. Experimental intraoperative photodynamic therapy for prostate cancer. 25th Annual Meeting of the American Society for Photobiology, St. Louis, MO, July 1997.
 10. Hamblin MR, Duska LR, Del Governatore M, Momma T, **Hasan T**. Tumor Targeting and Tissue Transport of Charged Poly-L-Lysine Chlorin *e6* Conjugates. 7th Congress of the European Society of Photobiology, Stresa, Italy, September, 1997.
 11. Trauner KB, Bamberg M, **Hasan T**. Photodynamic Treatment of Antigen-Induced Arthritis with BPD-MA and MRI Monitoring. 7th Congress of the European Society for Photobiology, Stresa, Italy, September 1997.
 12. Duska LR, Miller J, Hamblin M, **Hasan T**. Photodynamic Therapy with a Photoimmunoconjugate in Combination with Cisplatin Administration for the Treatment of Advanced Epithelial Ovarian Cancer. American Society of Clinical Oncology, Los Angeles, CA, May 1998.
 13. Birngruber R, Schmidt-Erfurth U, **Hasan T**. Photodynamic Therapy of Ocular Neovascularizations: Principle and Clinical Applications using Benzoporphyrin Derivative. Japan Chapter of the International Photodynamic Association, Osaka, Japan, June 1998.
 14. Hamblin MR, Penta P, Ortel B, **Hasan T**. Targeting Phototoxicity to Macrophages via Albumin Photosensitizer Conjugates. American Society for Photobiology, Snowbird, UT, July 1998.
 15. Hamblin MR, Miller JL, Rizvi I, Ortel B, Maytin EV, **Hasan T**. Mechanism of Differential Phototoxicity After Pegylation of Poly-L-Lysine Chlorin *e6* Conjugates, American Society for Photobiology, Snowbird, UT, July 1998.
 16. Moor ACE, Rizvi I, Savellano, **Hasan T**. The EGF Receptor as Target for Photosensitizer-Antibody Conjugates in the Photodynamic Treatment of Ovarian Cancer. FASEB 1999.
 17. Moor ACE, Rajagopalan K, Savellano MD, **Hasan T**. Photodynamic Treatment of Ovarian Cancer Cells Using Photosensitizer-Antibody Conjugates Directed Against the EGF-R, American Society for Photobiology, Washington, D.C., July 1999.
 18. Moor ACE, Rizvi I, Savellano MD, **Hasan T**. Photodynamic Treatment of Ovarian Cancer using the EGF-R as Specific Target for Photosensitizer Antibody Conjugates. European Society for Photobiology, Granada, Spain, September 1999, P187, p.165.
 19. Hamblin, MR, O'Donnell D, Murphy N, Rizvi I, **Hasan T**. Targeted Photoinactivation of Gram Negative Bacterial Contamination in Wounds. European Society for Photobiology, Granada, Spain, September 1999, 016, p. 96.
 20. Ortel B, Maytin EV, Brissette J, Chen N, Dotto P, **Hasan T**. Modulation of ALA-based PDT by Cellular Differentiation, European Society for Photobiology, Granada, Spain, September 1999, S137, p. 85.
 21. **Hasan T**, Moor A, Ortel B, Rizvi I., and Hamblin M., Targeted Photosensitization, Subcellular Targeting and Cell Death, 8th Congress, European Society for Photobiology, Granada, Spain, September 1999, S92, p. 73.
 22. **Hasan T**, Hamblin M, Moor A, Ortel B, Rizvi I, Savellano M. Selective Subcellular Localization of

- Photosensitizers and Consequent Phototoxicity, 3rd International Symposium on Photodynamic Diagnosis and Therapy in Clinical Practice, Innsbruck, Austria, October 1999.
23. **Hasan T.** New Aspects in Indocyanine-Green-Angiography, 4th International Symposium on ICG-Angiography, Baden-Baden, Germany, 1999.
 24. Moor A, Rizvi I, Savellano, Yu W, **Hasan T.** The EGF Receptor as Target for Photoimmunotherapy of Ovarian Cancer. American Society for Photobiology, San Francisco, 2000.
 25. **Hasan T,** Hamblin M, Moor A, Ortel B, Rizvi I, Savellano M. Targeted Photosensitization in the Optimization of PDT. American Society for Photobiology, San Francisco, 2000.
 26. Hamblin M, O'Donnell D, Murthy N, Contag C, **Hasan T.** Photodynamic Inactivation of Luminescent Bacteria in Contaminated and Infected Wounds in the Mouse. American Society for Photobiology, San Francisco, CA, 2000.
 27. Hamblin M, Del Governatore M, Shea C, Rizvi I, Molpus K, **Hasan T.** Experimental Photoimmunotherapy for Treatment of Hepatic Metastases of Colorectal Cancer in the Mouse, American Society for Photobiology, San Francisco, CA, 2000.
 28. Hamblin M, O'Donnell D, Murthy N, Rajagopalan K, Sherwood M, **Hasan T.** Photoinactivation of Antibiotic-Resistant Bacteria using Polycationic Photosensitizer Conjugates. American Society for Photobiology, San Francisco, CA, 2000.
 29. Hamblin M, Moor A, Ortel B, Rizvi I, Savellano M, **Hasan T.** Strategies for Enhanced Selectivity in Photosensitization., First International Conference on Porphyrins and Phthalocyanines (ICPP PDT Symposium, Dijon, France, 2000.
 30. Moor ACE, del Carmen MG, Mulder K, Rizvi I, Yu W, Dinh T, **Hasan T.** A New Treatment Modality for Ovarian Cancer: Epidermal Growth Factor Receptor Targeted Therapy in Combination with Photodynamic Treatment. American Association for Cancer Research, New Orleans, LA, 2001.
 31. Duska LR, Wimberly J, Deutsch TF, Haas J, Houck K, **Hasan T.** Detection of female lower genital tract dysplasia utilizing orally administered 5-Aminolevulinic acid (ALA) induced protoporphyrin IX. Society of Gynecologic Oncologists, Nashville, TN, 2001.
 32. Sullivan L, **Hasan T,** Wright M, Mankin H, Towle C. Light has chondroprotective effects on photosensitized cartilage. Orthopaedic Research Society, San Francisco, CA, 2001.
 33. Ortel B, Sharlin DS, O'Donnell DA, Maytin EV, **Hasan T.** Short-term differentiation therapy and PDT. American Society for Photobiology, Chicago, IL, 2001.
 34. Rizvi I, Rice W, Sharlin D, Dinh T, Yu W, **Hasan T.** Targeted photoimmunotherapy of epidermal growth factor receptor: mechanistic parameters governing phototoxic efficiency. 30th Annual Meeting, American Society for Photobiology, Quebec City, Canada, 2002.
 35. Rizvi I, del Carmen M, Moor A, Dinh T, **Hasan T.** Enhancement of epidermal growth factor receptor targeted treatment of ovarian cancer with photodynamic therapy. 30th Annual Meeting, American Society for Photobiology, Quebec City, Canada, 2002.
 36. Ortel B, Sinha A, Sharlin D, Maytin E, **Hasan T.** Order-dependent enhancement of ALA-PDT by chemotherapy. 30th Annual Meeting, American Society for Photobiology, Quebec City, Canada, 2002.
 37. **Hasan T.** Photodynamic Destruction of Mycobacteria in a New Animal Model for Localized Infection. 30th Annual Meeting, American Society for Photobiology, Quebec City, Canada, 2002.
 38. **Hasan T.** Photodynamic and Antiangiogenic Therapy: Local Control and Distant Metastasis. 30th Annual Meeting, American Society for Photobiology, Quebec City, Canada, 2002.
 39. Hamblin MR, Zahra T, Francis KP, and **Hasan T.** Targeted photodynamic therapy for Staphylococcus aureus soft tissue infections in vivo monitored by bioluminescence imaging. 30th Annual Meeting of the American Society for Photobiology, Quebec City, Canada, 2002.
 40. Hamblin MR, O'Donnell DA, Zahra T, Contag CH, McManus AT, and **Hasan T.** Targeted

- photodynamic therapy for infected wounds in mice. Optical Techniques for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XI, BioS 2002 Biomedical Optics, Photonics West, San Jose, CA, 2002.
41. Ortel B, Sinha AK, Sharlin D, **Hasan T**, Maytin EV. Order-dependent enhancement of ALA-PDT by chemotherapy in prostate cancer cells. AACR, Toronto, Canada 2003.
 42. **Hasan T**. Photochemical Effects in Laser-Tissue Interactions: Photodynamic Therapy, an Overview. SPIE Photonics West, San Jose, CA 2004.
 43. **Hasan T**, Solban N, Georgakoudi I, Ortel B, Lin C. Optical Imaging in the Mechanistic Understanding of Photodynamic Therapy. SPIE Photonics West, San Jose, CA 2004.
 44. **Hasan T**, Solban N, Georgakoudi I, Rice W, Benvides J, Lin C. Tumor Metastasis, Cell Type, Animal Species, and Tumor Cell Monitoring *in vivo*. SPIE Photonics West, San Jose, CA 2004.
 45. **Hasan T**. Photodynamic Therapy: A Photochemistry-Based Approach to Treatment and Diagnosis of Disease. Great Lakes Symposium, Cleveland, OH 2004.
 46. **Hasan T**, Solban N, Georgakoudi I, Rice W, Benvides J, Lin C. Photodynamic Therapy: Mechanisms of Optimization. ICCP-3, Medical Applications of Porphyrin-based compounds, New Orleans, LA 2004.
 47. Solban N, Georgakoudi I, Rice W, Sinha A, Selbo PK, Lin C, **Hasan T**. Molecular responses of prostate cancer to photodynamic therapy and *in vivo* imaging of circulating prostate cancer cells. American Society for Photobiology, Seattle, WA, 2004.
 48. Georgakoudi I, Solban N, Novak J, **Hasan T**, Lin CP. *In vivo* flow cytometry: A new method for monitoring circulating cancer cells. Optical Society of America, Miami, FL, 2004.
 49. Solban N, Rice W, Georgakoudi I, Szyner-Taub N, Benavides J, Johnson B, Lin C, **Hasan T**. Effect of Photodynamic Therapy on Prostate Cancer. Tumor Progression and Therapeutic Resistance, Philadelphia, PA, 2004.
 50. Lee S, Vu DH, Hinds MF, Davis SJ, **Hasan T**, Liang A. A diode laser-based singlet oxygen monitor for photodynamic therapy; in-vitro and in-vivo studies. Biomedical Optics Topical Meeting, Ft. Lauderdale, FL, 2006.
 51. **Hasan T**, Solban N, Chang S K, Rizvi I, Stepinac T, Liang A, Mail Z, Athar H. Molecular Response Based Combinations with PDT. European Society for Photobiology, Bath, UK, 2007.
 52. **Hasan T**, Verma S, Zheng Z, Sallum U, Athar H. Antimicrobial PDT: exploiting target cell function for selective photosensitizer delivery. European Society for Photobiology, Bath, UK, 2007.
 53. **Hasan T**, Verma S, Sallum U, Zheng Z. Strategies for targeted Photodynamic Therapy. International Conference on Porphyrins and Phthalocyanines (ICCP-5), Moscow, Russia, 2008.
 54. Hasan T. Getting optimal PDT response via molecular target identification. Photodynamic therapy and Photodiagnosis in Clinical Practice. Brixen, Italy, 2008.
 55. Hasan T. Approaches to selectivity in PDT. Photodynamic therapy and Photodiagnosis in Clinical Practice. Brixen, Italy, 2008.